Investor Presentation

Driving Strong Growth and Performance Delivering novel solutions to biomanufacturing challenges Addressing critical needs of COVID-19 programs Expanding Systems and consumables in Filtration and Chromatography; Building out Process Analytics Business Expanding manufacturing capacity, accelerating hiring 2020 Revenue Splits Analytics Proteins 22% 9% Chroma 20% CORE 83% Filtration 48% COVID 13% M&A 5% Gene Therapy 2020 Highlights $366M TOTAL REVENUE 36% REVENUE GROWTH 29% Organic 57.6% GROSS MARGIN 26.8% ADJ. OPERATING MARGIN $1.65 ADJ. EPS >400 NEW HIRES in 2020 RREPLIGEN INSPIRING ADVANCES IN BIOPROCESSING Guidance 2021* $655M-$665M TOTAL REVENUE 79%-82% REVENUE GROWTH 65%-68% Organic 59%-60% GROSS MARGIN 30%-31% ADJ. OPERATING MARGIN $2.86-$2.91 ADJ. EPS *Guidance as of 10/28/21 earnings call; see Appendix for GAAP to non- GAAP reconciliations LO 5

View entire presentation